SILICON VALLEY, CA - June 24, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it has converted its initial $100,000 convertible note into 10,000 shares of common stock of AiBtl BioPharma Inc. at a conversion price of $10 per share.

The conversion price is supported by an independent third-party valuation report, which estimated the current fair value of AiBtl’s equity. In addition, ABVC disclosed its intention to invest up to $20 million in AiBtl over time, further reinforcing its role as a lead strategic investor.

ABVC expects that AiBtl will utilize the additional funds to fulfill its licensing obligations and collaborate with global pharma partners to accelerate Phase III development. ABVC will continue executing its capital-light strategy by investing in innovative partners through a combined licensing and equity model. 

AiBtl currently holds exclusive global development and commercialization rights to ABVC’s two CNS drug candidates, ABV-1504 and ABV-1505, under a previously announced licensing agreement. The agreement includes equity, milestone payments and royalties, with each of ABVC and its subsidiary BioLite entitled to receive up to 23 million shares of AiBtl common stock (totaling 46 million shares), up to $7 million in cash milestone payments, and future sales-based royalties, if achieved.

“As both the licensing partner and anchor investor, ABVC is committed to AiBtl’s success,” said Dr. Uttam Patil, ABVC Chief Executive Officer. “This investment strengthens AiBtl’s ability to advance its pipeline, while also positioning ABVC to benefit from future milestone and royalty revenues.”

About AiBtl BioPharma Inc.

AiBtl BioPharma Inc. is a Delaware-based biopharmaceutical company focused on the development of botanical-based therapeutic candidates for central nervous system (CNS) disorders, including major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Leveraging a combination of traditional botanical knowledge and modern clinical research, AiBtl seeks to advance drug candidates derived from Polygala tenuifolia, a traditional medicinal herb. AiBtl operates with a strategic focus on Asia-Pacific markets and is exploring collaborative opportunities with global pharmaceutical partners to support late-stage development and commercialization. ABVC BioPharma currently holds a majority ownership stake in AiBtl.

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Forward-Looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:
Uttam Patil
Email: uttam@ambrivis.com

View the original release on www.newmediawire.com